FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3164815799> ?p ?o ?g. }

• W3164815799 endingPage "665" @default.
• W3164815799 startingPage "665.2" @default.
• W3164815799 abstract "Background: Skeletal muscle is known as one of the organ involvements of primary systemic vasculitis. 1,2 Muscle inflammation is detected by magnetic resonance imaging, and necrotizing vasculitis is proved by muscle biopsy. 3 As with systemic vasculitis or single organ vasculitis, glucocorticoid (GC) and immunosuppressants are used in its treatment. 4 There are not many reports about muscular vasculitis, and its long-term clinical course after initial treatment, including the rates of relapse and mortality, remains unclear. Objectives: To identify the predictors of relapse and mortality in patients with muscular vasculitis, especially focusing on the status of anti-neutrophil cytoplasmic antibody (ANCA). Methods: We retrospectively reviewed patients diagnosed with necrotizing vasculitis with muscle involvements in our hospital between 2004 and 2020. In all cases, muscular vasculitis was identified by muscle biopsy or magnetic resonance imaging. To focus on the clinical features of muscular vasculitis, we excluded patients with such severe organ involvements as cardiovascular, abdominal, cerebral, severe renal, and severe pulmonary involvements. We compared the 5-year cumulative incidence of relapse, the overall survival rate, and the dose of GC over 5 years between the ANCA-positive and ANCA-negative groups. A relapse was defined as any new or worsened state of disease activity requiring an escalation of GC dose. Gray’s method was used for assessing the cumulative incidence of relapse. The log-rank test was used for assessing overall survival. The Mann-Whitney U test was used for assessing the dose of GC. The possible factors for relapse in 5 years in a univariate analysis were selected for a multivariate analysis using the Cox proportional hazards model. Results: Forty-nine patients were enrolled. The median age of onset was 77 (69-82) years and 71.4% were women. There were 30 ANCA-positive patients (90.0% with anti-myeloperoxidase) and 19 ANCA-negative patients. The median age and the number of patients with renal involvements were higher in the ANCA-positive group than in the ANCA-negative group (73.0 ± 9.29 years vs. 79.5 ± 20.28 years, p=0.0062 and 7/30 [23.3%] vs. 0/19 [0.0%], p=0.034, respectively). The Birmingham Vasculitis Activity Score (ver. 3), the induction dose of GC, and the rate of immunosuppressants use were not significantly different between the two groups. During the observational period, 24 patients relapsed. The 5-year cumulative incidence of relapse was significantly higher in the ANCA-positive group than in the ANCA-negative group (p=0.026) (Figure 1). The Cox proportional hazards model revealed that the presence of ANCA was an independent risk factor for relapse (hazard ratio: 3.15; 95% confidence interval 1.06–9.38; p=0.040). During the observational period, 9 patients died (3 died from cancer, 1 from interstitial pneumonia, 1 from cerebral hemorrhage, 1 from infection, and 3 from unknown reasons). The ANCA-positive group exhibited a higher mortality rate than the ANCA-negative group without a statistical significance (p=0.12). The 5-year cumulative dose of GC was larger in the ANCA-positive group than in the ANCA-negative group without a statistical significance (14786 [11246–19138] mg vs. 10088 [7129–12634] mg, p=0.12). Conclusion: In muscular vasculitis, the presence of ANCA is an independent risk factor for long-term relapse. Stratified treatment depending on the ANCA status may reduce the relapse rate and the occurrence of side effects of GC in patients with muscular vasculitis. References: [1]Kitching AR et al. Nat Rev Dis Primers 2020; 6(1): 71. [2]Hernández-Rodríguez J et al. J Autoimmun 2014; 48-49: 84-9. [3]Ushiyama S et al. Rheumatol Int 2020; 40(10): 1667-74. [4]Ganeshanandan LR et al. Semin Arthritis Rheum 2020; 50(3): 503-8. Disclosure of Interests: None declared" @default.
• W3164815799 created "2021-06-07" @default.
• W3164815799 creator A5000361815 @default.
• W3164815799 creator A5013659565 @default.
• W3164815799 creator A5038553182 @default.
• W3164815799 creator A5048207427 @default.
• W3164815799 creator A5050988600 @default.
• W3164815799 creator A5072728823 @default.
• W3164815799 creator A5088420645 @default.
• W3164815799 date "2021-05-19" @default.
• W3164815799 modified "2023-09-25" @default.
• W3164815799 title "POS0824 THE LONG-TERM CLINICAL COURSE OF MUSCULAR VASCULITIS DEPENDING ON THE ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY STATUS: A RETROSPECTIVE OBSERVATIONAL STUDY" @default.
• W3164815799 doi "https://doi.org/10.1136/annrheumdis-2021-eular.815" @default.
• W3164815799 hasPublicationYear "2021" @default.
• W3164815799 type Work @default.
• W3164815799 sameAs 3164815799 @default.
• W3164815799 citedByCount "0" @default.
• W3164815799 crossrefType "journal-article" @default.
• W3164815799 hasAuthorship W3164815799A5000361815 @default.
• W3164815799 hasAuthorship W3164815799A5013659565 @default.
• W3164815799 hasAuthorship W3164815799A5038553182 @default.
• W3164815799 hasAuthorship W3164815799A5048207427 @default.
• W3164815799 hasAuthorship W3164815799A5050988600 @default.
• W3164815799 hasAuthorship W3164815799A5072728823 @default.
• W3164815799 hasAuthorship W3164815799A5088420645 @default.
• W3164815799 hasBestOaLocation W31648157991 @default.
• W3164815799 hasConcept C126322002 @default.
• W3164815799 hasConcept C142724271 @default.
• W3164815799 hasConcept C167135981 @default.
• W3164815799 hasConcept C2775934546 @default.
• W3164815799 hasConcept C2776015282 @default.
• W3164815799 hasConcept C2777374719 @default.
• W3164815799 hasConcept C2779134260 @default.
• W3164815799 hasConcept C2779999465 @default.
• W3164815799 hasConcept C71924100 @default.
• W3164815799 hasConcept C90924648 @default.
• W3164815799 hasConceptScore W3164815799C126322002 @default.
• W3164815799 hasConceptScore W3164815799C142724271 @default.
• W3164815799 hasConceptScore W3164815799C167135981 @default.
• W3164815799 hasConceptScore W3164815799C2775934546 @default.
• W3164815799 hasConceptScore W3164815799C2776015282 @default.
• W3164815799 hasConceptScore W3164815799C2777374719 @default.
• W3164815799 hasConceptScore W3164815799C2779134260 @default.
• W3164815799 hasConceptScore W3164815799C2779999465 @default.
• W3164815799 hasConceptScore W3164815799C71924100 @default.
• W3164815799 hasConceptScore W3164815799C90924648 @default.
• W3164815799 hasIssue "Suppl 1" @default.
• W3164815799 hasLocation W31648157991 @default.
• W3164815799 hasOpenAccess W3164815799 @default.
• W3164815799 hasPrimaryLocation W31648157991 @default.
• W3164815799 hasRelatedWork W1484034048 @default.
• W3164815799 hasRelatedWork W1923698495 @default.
• W3164815799 hasRelatedWork W1982793622 @default.
• W3164815799 hasRelatedWork W1988591658 @default.
• W3164815799 hasRelatedWork W2033027367 @default.
• W3164815799 hasRelatedWork W2102682498 @default.
• W3164815799 hasRelatedWork W2121394214 @default.
• W3164815799 hasRelatedWork W2122351559 @default.
• W3164815799 hasRelatedWork W2315104559 @default.
• W3164815799 hasRelatedWork W4327586977 @default.
• W3164815799 hasVolume "80" @default.
• W3164815799 isParatext "false" @default.
• W3164815799 isRetracted "false" @default.
• W3164815799 magId "3164815799" @default.
• W3164815799 workType "article" @default.